文献速递肝病消化道出血消化内镜

临床试验:卡维地洛对比食管静脉曲张套扎术在肝硬化患者静脉曲张出血一级预防中的多中心随机对照试验(CALIBRE试验)

Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial).
PubMed 文献 · Aliment Pharmacol Ther · 2025-04-16

CALIBRE为研究者发起的多中心随机对照开放标签试验,纳入肝硬化伴中大型未出血食管静脉曲张患者,随机接受卡维地洛12.5 mg每日一次或套扎术。因疫情提前终止,实际入组265例(为预期样本量的10%),1年内静脉曲张出血卡维地洛组5/133例(3.8%)vs 套扎组10/132例(7.6%),风险比0.50(95%CI 0.17-1.41),无统计学差异;两组严重不良事件各1例,无治疗相关死亡。

要点

  • 卡维地洛组1年内静脉曲张出血3.8% vs 套扎组7.6%,风险比0.50(95%CI 0.17-1.41),无统计学差异。
  • 两组严重不良事件各1例,无治疗相关死亡。
  • 试验因疫情提前终止,实际样本量为预期10%,把握度不足。

核心结论

  • 提前终止且把握度不足的CALIBRE试验显示,卡维地洛与套扎术在肝硬化伴中大型食管静脉曲张患者静脉曲张出血一级预防中无差异,未观察到安全性担忧。

研究设计与样本

  • CALIBRE为研究者发起的多中心随机对照开放标签试验,2019年1月22日至2022年8月31日从52个中心随机纳入265例(为预期样本量的10%),卡维地洛组133例、套扎组132例。
  • 纳入标准为肝硬化伴中大型未出血食管静脉曲张,干预为卡维地洛12.5 mg每日一次或套扎术,主要结局为随机后1年内任何静脉曲张出血。

主要发现

  • 1年内静脉曲张出血卡维地洛组5/133例(3.8%)vs 套扎组10/132例(7.6%),风险比0.50(95%CI 0.17-1.41),风险差-0.038(95%CI -0.094-0.017)。
  • 两组严重不良事件各1例,无治疗相关死亡。
  • 次要结局均无统计学显著差异;卡维地洛费用更低且质量调整生命年略多于套扎术。

局限性

  • 试验因疫情提前终止,实际样本量为预期样本量的10%,把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The superior efficacy of non-selective beta-blockers (NSBB) compared with variceal band ligation (VBL) in the primary prevention of variceal bleeding is uncertain. AIM: To compare carvedilol versus VBL for primary prevention of variceal bleeding. METHODS: CALIBRE was an investigator-initiated, multicentre, randomised, controlled, open-label trial. Participants were randomly assigned to 12.5 mg carvedilol once daily or VBL. Inclusion criteria were cirrhosis and medium to large oesophageal varices that had not bled. The primary outcome is any variceal bleeding within 1 year of randomisation. Secondary outcomes include survival, other complications of cirrhosis, quality of life, cost-effectiveness and adverse events. Recruitment closed early, mainly due to the impact of the pandemic. RESULTS: 265 participants (10% of the intended sample size) from 52 sites were randomised to carvedilol (n = 133) or VBL (n = 132) between 22 January 2019 and 31 August 2022. 5/133 participants (3.8%) in the carvedilol arm vs. 10/132 participants (7.6%) in the VBL arm experienced variceal bleeding (risk ratio 0.50 (95% confidence interval [CI]; 0.17-1.41); risk difference - 0.038 (95% CI; -0.094-0.017)). Serious adverse events occurred in one participant in each treatment arm, with no treatment-related deaths. Of the secondary outcomes, there were no statistically significant differences. Carvedilol was cheaper and resulted in slightly more quality-adjusted life years than VBL. CONCLUSIONS: The early terminated and, thus, underpowered CALIBRE trial showed no difference between carvedilol and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. No untoward safety concerns were noted. TRIAL REGISTRATION: ISRCTN73887615.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tripathi D, Handley K, Holden L, et al. Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial). Aliment Pharmacol Ther. 2025. PMID: 40241373. doi:10.1111/apt.70080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。